Techno Medica (6678) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended December 31, 2024, was ¥6,447 million, up 0.4% year-over-year, supported by strong overseas sales and stable demand for consumables.

• Operating profit declined 37.0% year-over-year to ¥584 million due to increased R&D and personnel costs.

• Net profit fell 34.0% year-over-year to ¥427 million, reflecting higher expenses despite stable sales.

• Overseas sales ratio increased by 5.4 points to 16.9%, driven by growth in Southeast Asia and China.

Financial highlights

• Gross profit was ¥3,244 million, up 0.5% year-over-year.

• SG&A expenses rose 15.6% year-over-year to ¥2,659 million.

• Ordinary profit was ¥589 million, down 37.2% year-over-year.

• EPS for the period was ¥61.66, compared to ¥80.04 in the prior year.

Outlook and guidance

• Full-year revenue forecast remains unchanged at ¥10,000 million, a 2.8% decrease year-over-year.

• Full-year operating profit forecast is ¥1,400 million, down 23.9% year-over-year.

• Net profit for the year is projected at ¥970 million, a 28.0% decrease year-over-year.

• No revision to previously announced guidance.